Tasimelteon - CAS 609799-22-6
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Tasimelteon
Catalog Number:
B0084-072984
Synonyms:
BMS-214,778; BMS-214778; BMS214778; BMS 214778. VEC-162; VEC162; VEC 162. Trade name: Hetlioz.
CAS Number:
609799-22-6
Description:
Tasimelteon (trade name Hetlioz) is a drug approved by the FDA solely for the treatment of non-24-hour sleep–wake disorder (often designated as N24HSWD) in totally blind adults. It is a selective agonist for the melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, similar to other members of the melatonin receptor agonist class of which ramelteon (2005) and agomelatine (2009) were the first approved.
Molecular Weight:
245.32
Molecular Formula:
C15H19NO2
Quantity:
Grams-Kilos
Quality Standard:
In-house Standard
COA:
Certificate of Analysis-Tasimelteon 609799-22-6 B16TSMT0425  
MSDS:
Inquire
Canonical SMILES:
CCC(=O)NC[C@@H]1C[C@H]1C2=C3CCOC3=CC=C2
InChI:
InChI=1S/C15H19NO2/c1-2-15(17)16-9-10-8-13(10)11-4-3-5-14-12(11)6-7-18-14/h3-5,10,13H,2,6-9H2,1H3,(H,16,17)/t10-,13+/m0/s1
InChIKey:
PTOIAAWZLUQTIO-GXFFZTMASA-N
Targets:
Melatonin Receptor
Catalog Number Size Price Stock Quantity
B0084-072984 100 mg $498 In stock
B0084-072984 1 g $899 In stock
Bulk Inquiry
Chemical Structure
CAS 609799-22-6 Tasimelteon

Related Melatonin Receptor Products


CAS 196597-26-9 Ramelteon

Ramelteon
(CAS: 196597-26-9)

Ramelteon has high affinity with recombinant human MT1 and MT2 receptors with pKi of 10.05 and 9.70, respectively.

CAS 609799-22-6 Tasimelteon

Tasimelteon
(CAS: 609799-22-6)

Tasimelteon (trade name Hetlioz) is a drug approved by the FDA solely for the treatment of non-24-hour sleep–wake disorder (often designated as N24HSWD) in tota...

LY 156735
(CAS: 118702-11-7)

This active molecular is high affinity nonselective melatonin receptors MT1 and MT2 agonist which is under development for the treatment of insomnia and other s...

Reference Reading


1.Jet Lag and Psychotic Disorders
Gregory Katz. Curr Psychiatry Rep (2011) 13:187–192
Newly developed melatonin agonist tasimelteon (VEC-162) has been evaluated recently in phase 2 and phase 3 randomized, double-blind, placebo-controlled, parallelgroup studies for treatment of transient insomnia after sleep–time shift. Results were encouraging, and although they were not yet specifically applied to jet lag symptoms, they showed that after an abrupt advance in sleep time, tasimelteon improved sleep initiation and maintenance concurrently with a shift in endogenous circadian rhythms.
2.Circadian-Based Therapies for Circadian Rhythm Sleep-Wake Disorders
Helen J. Burgess & Jonathan S. Emens. Curr Sleep Medicine Rep
There were two new publications concerning blind individuals with N24SWD. Most important was Lockley et al.’s study of the drug tasimelteon in this population which became the first medication approved by the FDA for the treatment of any CRSWD. The study was a randomized, placebo controlled study in 84 individuals with N24SWD comparing 20 mg of tasimelteon and placebo administered 1 h before a target bedtime. Tasimelteon was found to safely and effectively treat individuals with N24SWD: entrainment (synchronization to the 24-h day) occurred in 20 % (8 of 40) of patients receiving the drug compared with 3 % (1 of 38) receiving placebo. As noted in the AASM CRSWD practice guideline, the entrainment rate was lower than the 67 % entrainment rate (12 of 18 patients) found in the metaanalysis of melatonin treatment in N24SWD. However, as noted by the authors themselves, this may have been because entrainment was assessed after just 1 month of treatment. Such a theory is borne out by the higher rates of entrainment found during the longer, open label treatment with tasimelteon. The tasimelteon study also demonstrated improvements (increases and decreases, respectively) in nighttime and daytime sleep (as measured by the worst quartiles of treatment days compared to baseline). Of note, the tasimelteon study could also be considered to include a component of prescribed sleep/wake scheduling as subjects were instructed to maintain selfselected 9-h sleep opportunities with bedtimes within a 4-h range (21:00 to 01:00). The second new publication in N24SWD was a small placebo controlled study by St. Hilaire and Lockley looking at the effects of caffeine on entrainment in three blind individuals with the disorder. Caffeine (150 mg at 10 am) failed to entrain the subjects although it did improve daytime alertness in the setting of circadian misalignment.